株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

てんかん: パイプライン分析

Epilepsy - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232793
出版日 ページ情報 英文 421 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
てんかん: パイプライン分析 Epilepsy - Pipeline Review, H2 2016
出版日: 2016年08月24日 ページ情報: 英文 421 Pages
概要

てんかんは、脳の神経細胞の集まりによって作られた異常信号が伝達されるというのが特徴である神経障害で、発作を引き起こします。この障害は、感覚が突然断絶したり、短い間に意識が無かったり、痙攣をおこしたりします。てんかんの主な原因には、出生時の低酸素、出産時あるいは青年期の事故による頭部の怪我、脳腫瘍、結節硬化症などといった脳損傷につながる遺伝子Disease、髄膜炎や脳炎などのような感染症、脳卒中やその他の脳障害などが挙げられます。 主な症侯は、繰り返し起きる発作や、脱力感、不安神経症、意識喪失、筋肉の収縮あるいは痙攣などが起こります。

当レポートでは、てんかんの治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • てんかんの概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Acorda Therapeutics, Inc.
  • Adamas Pharmaceuticals, Inc.
  • Advicenne Pharma
  • Aeolus Pharmaceuticals, Inc.
  • Aequus Pharmaceuticals Inc.
  • Aestus Therapeutics, Inc.
  • Alexza Pharmaceuticals, Inc.
  • Anavex Life Sciences Corp.
  • Asklepios BioPharmaceutical, Inc.
  • アステラス製薬
  • Bial - Portela & Ca, S.A.
  • BioCrea GmbH
  • Biogen, Inc.
  • Bionomics Limited
  • Biovista Inc.
  • Biscayne Pharmaceuticals, Inc.
  • Catalyst Pharmaceutical Partners, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • D-Pharm Ltd.
  • エーザイ
  • Grifols, S.A.
  • GW Pharmaceuticals Plc
  • H. Lundbeck A/S
  • Hyundai Pharmaceutical Co., Ltd.
  • INSYS Therapeutics, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Iproteos S.L.
  • Johnson & Johnson
  • Knopp Biosciences LLC
  • Lipicard Technologies Limited
  • Marathon Pharmaceuticals, LLC
  • Marinus Pharmaceuticals, Inc.
  • MedGenesis Therapeutix Inc.
  • Nemus Bioscience, Inc.
  • Neurelis, Inc.
  • Neurocrine Biosciences, Inc.
  • Neuron Biopharma SA
  • Novartis AG
  • OPKO Health, Inc.
  • Pfizer Inc.
  • PharmatrophiX, Inc.
  • Promius Pharma, LLC
  • PTC Therapeutics, Inc.
  • Retrophin Inc.
  • RODES Inc.
  • Sage Therapeutics, Inc.
  • Saniona AB
  • SciFluor Life Sciences, LLC
  • SK Biopharmaceuticals Co., Ltd.
  • 大日本住友製薬
  • 武田薬品工業
  • Trillium Therapeutics Inc.
  • Turing Pharmaceuticals AG
  • UCB S.A.
  • Ultragenyx Pharmaceutical Inc.
  • Upsher-Smith Laboratories, Inc.
  • Vichem Chemie Research Ltd.
  • VistaGen Therapeutics , Inc.
  • Xenon Pharmaceuticals Inc.
  • XERIS Pharmaceuticals, Inc.
  • Zogenix, Inc.
  • Zynerba Pharmaceuticals, Inc.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 2-DG
  • ADS-4101
  • ADV-6208
  • ADV-6770
  • AEOL-1114B
  • AEOL-11203
  • AEOL-11207
  • アルプラゾラム
  • AMPX-0079
  • ANAVEX-273
  • ataluren
  • AV-101
  • AVL-5189
  • BIS-001
  • BNP-TLE
  • BPS-015 SR
  • ブリバラセタム
  • BVA-601
  • カンナビジオール
  • カルバマゼピン
  • CCG-63802
  • 中枢神経系障害向け細胞療法
  • CHEC-9
  • CKD-903
  • クロバザム
  • CNV-1061436
  • コシントロピン
  • CPP-115
  • CUR-1916
  • ジアゼパム
  • DP-VPA
  • てんかん治療薬
  • てんかん・行動障害向けMAPK阻害薬
  • エピディオレックス
  • エスリカルバゼピン酢酸エステル
  • エベロリムス
  • 塩酸フェンフルラミン
  • fosphenytoin sodium
  • ganaxolone
  • てんかん向け神経ペプチド Y 受容体 Y2・Y5活性遺伝子療法
  • GWP-42006
  • ヒスタミン二塩酸塩
  • ヒト免疫グロブリン
  • INV-170
  • IPR-131
  • IPR-96
  • IPRO-003
  • JNJ-40411813
  • KM-113
  • KM-314
  • ラコサミド
  • ラモトリギン
  • レベチラセタム
  • リアテルミン
  • LM22A-4
  • ロラゼパム
  • LSPGR-1
  • LT-4121
  • LT-4122
  • LT-4123
  • LT-4124
  • LT-4125
  • LT-4126
  • magnesium valproate hydrate
  • MB-003
  • ミダゾラム塩酸塩
  • MP-101
  • MRS-5474
  • naluzotan hydrochloride
  • NB-23R1
  • NGT-168
  • NH-34
  • NRP-2945
  • NST-0037
  • NST-0076
  • ドラベ症候群向けオリゴヌクレオチド
  • ペランパネル
  • プレガバリン
  • プロポフォールヘミスクシナート
  • SAGE-217
  • SAGE-689
  • SCT-66
  • selurampanel
  • sepranolone
  • SF-0034
  • SGE-872
  • シンバスタチン
  • 癌性疼痛・てんかん向けナトリウムチャネル遮断薬 1
  • てんかん向け小分子 2
  • 癌性疼痛・てんかん向けナトリウムチャネル遮断薬 2
  • てんかん向け小分子 3
  • ナトリウムチャネル遮断薬 癌性疼痛・てんかん向け小分子 3
  • てんかん向け小分子 4
  • てんかん向け小分子
  • 脳卒中・てんかん向け小分子
  • てんかん・疼痛向け Activate Kv7.2/Kv7.3チャネル活性剤
  • てんかん向け GABAA受容体サブユニットα-4/γ作動薬
  • 神経疾患向け mGluR5/mGluR6拮抗薬
  • ラベ症候群向け Nav1.6遮断薬
  • 片頭痛・てんかん重積症向け GABAトランスアミナーゼ阻害剤
  • てんかん向け小分子 1
  • てんかん向け小分子 2
  • てんかん向け小分子 3
  • てんかん向け小分子 4
  • 中枢神経系障害向け小分子
  • てんかん向け小分子
  • 発作向け小分子
  • 中枢神経向け GABAA受容体活性剤/NMDA受容体拮抗薬
  • 神経障害痛・てんかん・耳鳴り向け Kv7活性剤
  • 中枢神経・代謝障害耳鼻咽喉科の病期向け TrkB受容体活性剤
  • てんかん向けGABA-A 受容体作動薬
  • てんかん・自閉症向け GABAA-Beta 2受容体作動薬
  • 中枢神経系障害向け TLR-4拮抗薬
  • てんかん・腫瘍学向けダイナミン阻害剤
  • レノックス・ガストー症候群向け電位開口型ナトリウムチャネル阻害剤
  • スルチアム
  • TAK-935
  • TF-0081
  • TG-4155
  • トピラマート
  • TRP-001
  • TUR-004
  • TUR-005
  • UCB-0942
  • UX-007
  • VAD-1
  • VAD-2
  • VB-3323
  • VID-45110
  • VU-0456810
  • YKP-3089
  • Z-944
  • ZYN-002
  • ■最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8401IDB

Summary

Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2016', provides an overview of the Epilepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Epilepsy
  • The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects
  • The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Epilepsy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Epilepsy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Epilepsy Overview
  • Therapeutics Development
  • Epilepsy - Therapeutics under Development by Companies
  • Epilepsy - Therapeutics under Investigation by Universities/Institutes
  • Epilepsy - Pipeline Products Glance
  • Epilepsy - Products under Development by Companies
  • Epilepsy - Products under Investigation by Universities/Institutes
  • Epilepsy - Companies Involved in Therapeutics Development
  • Epilepsy - Therapeutics Assessment
  • Drug Profiles
  • Epilepsy - Dormant Projects
  • Epilepsy - Discontinued Products
  • Epilepsy - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Epilepsy, H2 2016
  • Number of Products under Development for Epilepsy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Advicenne, H2 2016
  • Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
  • Epilepsy - Pipeline by Aestus Therapeutics, Inc., H2 2016
  • Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Anavex Life Sciences Corp., H2 2016
  • Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016
  • Epilepsy - Pipeline by Astellas Pharma Inc., H2 2016
  • Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H2 2016
  • Epilepsy - Pipeline by BioCrea GmbH, H2 2016
  • Epilepsy - Pipeline by Biogen Inc, H2 2016
  • Epilepsy - Pipeline by Bionomics Limited, H2 2016
  • Epilepsy - Pipeline by Biovista Inc., H2 2016
  • Epilepsy - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by D-Pharm Ltd., H2 2016
  • Epilepsy - Pipeline by Eisai Co., Ltd., H2 2016
  • Epilepsy - Pipeline by Glialogix, Inc., H2 2016
  • Epilepsy - Pipeline by Grifols, S.A., H2 2016
  • Epilepsy - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Epilepsy - Pipeline by H. Lundbeck A/S, H2 2016
  • Epilepsy - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Epilepsy - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Epilepsy - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Iproteos S.L., H2 2016
  • Epilepsy - Pipeline by Johnson & Johnson, H2 2016
  • Epilepsy - Pipeline by Knopp Biosciences LLC, H2 2016
  • Epilepsy - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Epilepsy - Pipeline by Lipicard Technologies Limited, H2 2016
  • Epilepsy - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016
  • Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016
  • Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Neurelis, Inc., H2 2016
  • Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H2 2016
  • Epilepsy - Pipeline by Neuron Biopharma SA, H2 2016
  • Epilepsy - Pipeline by Novartis AG, H2 2016
  • Epilepsy - Pipeline by OPKO Health, Inc., H2 2016
  • Epilepsy - Pipeline by Ovid Therapeutics Inc., H2 2016
  • Epilepsy - Pipeline by Pfizer Inc., H2 2016
  • Epilepsy - Pipeline by PharmatrophiX, Inc., H2 2016
  • Epilepsy - Pipeline by Promius Pharma, LLC, H2 2016
  • Epilepsy - Pipeline by PTC Therapeutics, Inc., H2 2016
  • Epilepsy - Pipeline by Retrophin Inc., H2 2016
  • Epilepsy - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Epilepsy - Pipeline by Saniona AB, H2 2016
  • Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H2 2016
  • Epilepsy - Pipeline by Shire Plc, H2 2016
  • Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Epilepsy - Pipeline by Suda Ltd, H2 2016
  • Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Epilepsy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Epilepsy - Pipeline by Trillium Therapeutics Inc., H2 2016
  • Epilepsy - Pipeline by Turing Pharmaceuticals AG , H2 2016
  • Epilepsy - Pipeline by UCB S.A., H2 2016
  • Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016
  • Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016
  • Epilepsy - Pipeline by Vichem Chemie Research Ltd., H2 2016
  • Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H2 2016
  • Epilepsy - Pipeline by Vitality Biopharma Inc, H2 2016
  • Epilepsy - Pipeline by Xenon Pharmaceuticals Inc., H2 2016
  • Epilepsy - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Zogenix, Inc., H2 2016
  • Epilepsy - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Epilepsy - Dormant Projects, H2 2016
  • Epilepsy - Dormant Projects (Contd..1), H2 2016
  • Epilepsy - Dormant Projects (Contd..2), H2 2016
  • Epilepsy - Dormant Projects (Contd..3), H2 2016
  • Epilepsy - Dormant Projects (Contd..4), H2 2016
  • Epilepsy - Dormant Projects (Contd..5), H2 2016
  • Epilepsy - Dormant Projects (Contd..6), H2 2016
  • Epilepsy - Dormant Projects (Contd..7), H2 2016
  • Epilepsy - Dormant Projects (Contd..8), H2 2016
  • Epilepsy - Dormant Projects (Contd..9), H2 2016
  • Epilepsy - Discontinued Products, H2 2016
  • Epilepsy - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Epilepsy, H2 2016
  • Number of Products under Development for Epilepsy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top